| Not Yet Recruiting | PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NCT07043907 | Shenzhen Celconta Life Science Co., Ltd. | Phase 2 |
| Active Not Recruiting | Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC NCT05894889 | Peking University | Phase 2 |
| Recruiting | Pathological Response After Neoadjuvant Treatment on NSCLC NCT05167487 | Fundación GECP | — |
| Active Not Recruiting | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) NCT04776447 | Fundación GECP | Phase 2 |
| Active Not Recruiting | CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell L NCT04062708 | Alliance Foundation Trials, LLC. | Phase 2 |
| Completed | Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consoli NCT03916419 | Washington University School of Medicine | Phase 2 |
| Active Not Recruiting | Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery NCT03433469 | University of California, San Francisco | Phase 2 |
| Terminated | Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Ca NCT03366766 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Unknown | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That C NCT03048500 | Northwestern University | Phase 2 |
| Completed | Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer NCT02947386 | Roswell Park Cancer Institute | Phase 1 |
| Terminated | Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC NCT02987998 | Nathan Pennell, MD, PhD | Phase 1 |
| Completed | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 NCT03049618 | University of Southern California | Phase 2 |
| Unknown | Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients NCT03053856 | Samsung Medical Center | Phase 2 |
| Completed | TG4010 and Nivolumab in Patients With Lung Cancer NCT02823990 | Megan Daly, MD | Phase 2 |
| Completed | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors NCT02897375 | Emory University | Phase 1 |
| Completed | S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) NCT02728596 | SWOG Cancer Research Network | N/A |
| Completed | Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell L NCT02879994 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Smal NCT02621398 | Rutgers, The State University of New Jersey | Phase 1 |
| Withdrawn | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery an NCT02567396 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomog NCT02819024 | Barbara Ann Karmanos Cancer Institute | N/A |
| Completed | Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer NCT02655913 | Clifford Hospital, Guangzhou, China | Phase 1 / Phase 2 |
| Withdrawn | Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell NCT02607423 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Terminated | Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Remove NCT02566421 | Wake Forest University Health Sciences | N/A |
| Completed | Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib NCT02364609 | Jonathan Riess | Phase 1 |
| Active Not Recruiting | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or NCT02495896 | University of Southern California | Phase 1 |
| Withdrawn | Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors NCT01971489 | Roswell Park Cancer Institute | Phase 1 |
| Completed | 18F-FSPG PET/CT for Cancer Patients on Therapy NCT02599194 | Andrei Iagaru | Phase 2 |
| Completed | Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuita NCT02262325 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Completed | Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non NCT02243748 | City of Hope Medical Center | N/A |
| Terminated | Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC NCT02276560 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Completed | Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell NCT01958372 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Completed | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III NCT02186847 | NRG Oncology | Phase 2 |
| Completed | Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV No NCT02245100 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | — |
| Terminated | Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surg NCT02134886 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer NCT02059889 | Virginia Commonwealth University | N/A |
| Completed | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Ce NCT01737502 | Mayo Clinic | Phase 1 / Phase 2 |
| Withdrawn | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC NCT02059967 | Virginia Commonwealth University | Phase 1 |
| Completed | Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed b NCT01854684 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients NCT01999881 | University of Wisconsin, Madison | N/A |
| Terminated | Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer NCT01857271 | Albert Einstein College of Medicine | Phase 2 |
| Withdrawn | Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Canc NCT02017925 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers NCT01935336 | University of Colorado, Denver | Phase 2 |
| Completed | PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stag NCT02073968 | Albert Einstein College of Medicine | Phase 2 |
| Terminated | Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Under NCT01886573 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer NCT01935947 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung C NCT01781741 | Roswell Park Cancer Institute | EARLY_Phase 1 |
| Completed | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675 | Sanjiv Sam Gambhir | Phase 1 / Phase 2 |
| Completed | Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer NCT01741636 | City of Hope Medical Center | N/A |
| Completed | Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorect NCT01726296 | Fox Chase Cancer Center | N/A |
| Terminated | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer NCT01707823 | Vanderbilt-Ingram Cancer Center | EARLY_Phase 1 |
| Unknown | An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) NCT01711697 | Emory University | Phase 1 |
| Not Yet Recruiting | Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Canc NCT01595074 | National Cancer Institute (NCI) | — |
| Terminated | Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot B NCT01411098 | University of Washington | Phase 1 |
| Withdrawn | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer NCT01383668 | Mayo Clinic | Phase 1 |
| Terminated | Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer NCT01342770 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lu NCT01314677 | City of Hope Medical Center | N/A |
| Active Not Recruiting | Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination NCT01345851 | Jonsson Comprehensive Cancer Center | N/A |
| Completed | Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer NCT01457469 | Wake Forest University Health Sciences | Phase 1 |
| Terminated | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Ur NCT01282333 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer NCT01076231 | Abramson Cancer Center at Penn Medicine | Phase 1 / Phase 2 |
| Completed | A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NCT00963807 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-s NCT00738881 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small NCT00778167 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III NCT00662311 | University of Washington | Phase 1 / Phase 2 |
| Completed | Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer NCT00387465 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Adv NCT00369551 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection NCT00087269 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer NCT00093756 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-S NCT00074022 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carc NCT00063895 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer NCT00078390 | Shionogi | Phase 1 / Phase 2 |
| Completed | Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Remov NCT00049543 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III N NCT00042835 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell NCT00040794 | National Cancer Institute (NCI) | Phase 2 |
| Completed | EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer NCT02154399 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III N NCT00020709 | National Cancer Institute (NCI) | Phase 3 |
| Completed | FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Can NCT00020202 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non NCT00005838 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer NCT00005065 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer NCT00003869 | National Cancer Institute (NCI) | Phase 3 |